David Schenkein - Feb 22, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as Attorney in Fact for David Schenkein
Stock symbol
AGIO
Transactions as of
Feb 22, 2022
Transactions value $
-$22,043
Form type
4
Date filed
2/23/2022, 03:09 PM
Previous filing
Jun 4, 2021
Next filing
May 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +2.78K +2.43% $0.00 117K Feb 22, 2022 Direct
transaction AGIO Common stock Tax liability -$22K -758 -0.65% $29.08 116K Feb 22, 2022 Direct
holding AGIO Common stock 79.1K Feb 22, 2022 See footnote F1
holding AGIO Common stock 271K Feb 22, 2022 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Options Exercise $0 -2.78K -100% $0.00* 0 Feb 22, 2022 Common stock 2.78K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F2 Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F3 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4 The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.